Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand.

IF 4 2区 医学 Q1 PSYCHIATRY Australian and New Zealand Journal of Psychiatry Pub Date : 2024-10-01 Epub Date: 2024-04-01 DOI:10.1177/00048674241242315
Alistair Carroll, Adam Bayes, Mark Montebello, Jonathan Brett, Shalini Arunogiri, John B Saunders, Colleen K Loo
{"title":"Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand.","authors":"Alistair Carroll, Adam Bayes, Mark Montebello, Jonathan Brett, Shalini Arunogiri, John B Saunders, Colleen K Loo","doi":"10.1177/00048674241242315","DOIUrl":null,"url":null,"abstract":"<p><p>Ketamine is a restricted and regulated medication in Australia and New Zealand, which has implications when considering treatment for patients with treatment-resistant depression and a history of illicit drug use, abuse or dependence. Regulations governing prescription of ketamine for treatment-resistant depression vary between jurisdictions in Australia and New Zealand, though most restrict use in those with drug dependence. There is substantial variation in definitions of drug dependence used in each jurisdiction, and between the legal and clinical definitions, with the latter specified in the current International Classification of Diseases, Eleventh Revision and <i>Diagnostic and Statistical Manual of Mental Disorders</i>, Fifth Edition. This paper reviews the literature assessing the risk of ketamine misuse and dependence in patients with a history of illicit drug use, abuse or dependence and presents recommendations for psychiatrists who prescribe ketamine in such patients with treatment-resistant depression.</p>","PeriodicalId":8589,"journal":{"name":"Australian and New Zealand Journal of Psychiatry","volume":" ","pages":"831-838"},"PeriodicalIF":4.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian and New Zealand Journal of Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00048674241242315","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Ketamine is a restricted and regulated medication in Australia and New Zealand, which has implications when considering treatment for patients with treatment-resistant depression and a history of illicit drug use, abuse or dependence. Regulations governing prescription of ketamine for treatment-resistant depression vary between jurisdictions in Australia and New Zealand, though most restrict use in those with drug dependence. There is substantial variation in definitions of drug dependence used in each jurisdiction, and between the legal and clinical definitions, with the latter specified in the current International Classification of Diseases, Eleventh Revision and Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. This paper reviews the literature assessing the risk of ketamine misuse and dependence in patients with a history of illicit drug use, abuse or dependence and presents recommendations for psychiatrists who prescribe ketamine in such patients with treatment-resistant depression.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
澳大利亚和新西兰的药物依赖性与开氯胺酮治疗耐药性抑郁症。
在澳大利亚和新西兰,氯胺酮是一种受限制和管制的药物,这对考虑治疗患有难治性抑郁症并有非法药物使用、滥用或依赖史的患者有一定影响。澳大利亚和新西兰各辖区对氯胺酮治疗耐药性抑郁症的处方管理规定各不相同,但大多数辖区都限制对药物依赖患者使用氯胺酮。各司法管辖区对药物依赖的定义以及法律定义和临床定义之间存在很大差异,后者在现行的《国际疾病分类》第十一次修订版和《精神疾病诊断与统计手册》第五版中均有明确规定。本文回顾了评估有非法药物使用、滥用或依赖史的患者误用和依赖氯胺酮风险的文献,并向为此类难治性抑郁症患者开具氯胺酮处方的精神科医生提出了建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.00
自引率
2.20%
发文量
149
审稿时长
6-12 weeks
期刊介绍: Australian & New Zealand Journal of Psychiatry is the official Journal of The Royal Australian and New Zealand College of Psychiatrists (RANZCP). The Australian & New Zealand Journal of Psychiatry is a monthly journal publishing original articles which describe research or report opinions of interest to psychiatrists. These contributions may be presented as original research, reviews, perspectives, commentaries and letters to the editor. The Australian & New Zealand Journal of Psychiatry is the leading psychiatry journal of the Asia-Pacific region.
期刊最新文献
Self-poisoning in young Australians: The impact of COVID-19 and recent trends following easing of restrictions. Letters to the Editor: Differential effects of access restriction to a highway bridge on suicide numbers by jumping. Extending the reach of involuntary treatment to substance use disorders: Is it 'compassionate' or coercive care? Policy implications of the 2020-22 Australian study of mental health and wellbeing. Glutamatergic neurotransmission in schizophrenia: A systematic review and quantitative synthesis of proton magnetic resonance spectroscopy studies across schizophrenia spectrum disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1